Jaguar health to present december 5 at the medinvest oncology investor conference

Top line data for jaguar health's pivotal phase 3 ontarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming san francisco, ca / accesswire / november 30, 2023 / jaguar health, inc. (nasdaq:jagx) today announced that lisa conte, the company's founder, president and ceo, will present virtually on december 5, 2023 at the medinvest oncology investor conference. participation instructions for jaguar health's virtual presentation at the medinvest oncology investor conference when: tuesday, december 5, 2023 from 9:55 am - 10:10 am pacific standard time registration link for presentation: click here about the phase 3 ontarget clinical trial the ontarget trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis (prevention) of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy - an indication napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (ciob) - which includes symptoms such as chronic debilitating diarrhea (loose and/or watery stools), urgency, and bowel incontinence.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score